CALC

CalciMedica, Inc.

4.69 USD
+0.52 (+12.47%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

CalciMedica, Inc. stock is down -6.94% since 30 days ago. The next earnings date is Aug 8, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 1 July’s closed higher than June. 100% of analysts rate it a buy.

About CalciMedica, Inc.

CalciMedica, Inc. focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials. GB-401, an implant formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma.

  • HC Wainwright & Co.
    Tue Jul 9, 11:49
    buy
    confirm
  • HC Wainwright & Co.
    Thu Jun 27, 11:54
    buy
    confirm